The endocannabinoid system: potential for reducing cardiometabolic risk.
Irving Institute for Clinical and Translational Research, Department of Medicine, College of Physicians and Surgeons of Columbia University, New York, New York, USA. hng1@columbia.edu
Henry N
HN
Ginsberg
Stephen C
SC
Woods
D000818:Animals; D063387:Cannabinoid Receptor Antagonists; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism*; D063388:Endocannabinoids; D006801:Humans; D051379:Mice; D009765:Obesity / Q000188:drug therapy / Q000378:metabolism*; D010880:Piperidines / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D043882:Receptors, Cannabinoid / Q000378:metabolism*; D000077285:Rimonabant
D063387:Cannabinoid Receptor Antagonists; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D010880:Piperidines; D011720:Pyrazoles; D043882:Receptors, Cannabinoid; D000077285:Rimonabant